The news about Regeneron Pharmaceuticals, Inc. (REGN) presents a mixed bag of updates. On one hand, the company has seen their shares sold by a variety of major investment groups such as Illinois Municipal Retirement Fund, Trifecta Capital Advisors LLC, and NewEdge Wealth LLC. In contrast, their shares have also been purchased by other groups such as Anchor Capital Advisors LLC and FourThought Financial Partners LLC. The company also faces potential legal issues with class action lawsuits and investor notices being highlighted. Notably though, Regeneron's Multiple Myeloma drug cleared a significant EU regulatory hurdle, and appears to be making strides with their gene therapy solution for deaf children. Despite some optimistic findings and strong Q4 2024 earnings, some analysts have cut the price target for Regeneron, implying a potential future slowdown. Irregardless, other analysts remain bullish on the stock, suggesting it is one of the top choices for growth.
Regeneron Pharmaceuticals REGN News Analytics from Thu, 02 Jan 2025 08:00:00 GMT to Sat, 01 Mar 2025 08:04:26 GMT - Rating -3 - Innovation 5 - Information 8 - Rumor -2
